Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bast

Showing results (361-370 of 560) with videos related to

Pageof 56
Sort By:
Biochimica Et Biophysica Acta|June 22, 2001
Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHIR Z Luo, H Peng, F Xu, et al.
Cancer Research|December 1, 1987
Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumorsW P Peters, W D Henner, L B Grochow, et al.
International Journal of Cancer|October 15, 1994
The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxinF J Xu, C M Boyer, D S Bae, et al.
Gynecologic Oncology|May 29, 2007
Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragmentDonna Badgwell, Zhen Lu, Laurence Cole, et al.
Journal of the National Cancer Institute|August 5, 2011
The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cellsXiao-Feng Le, Weiqun Mao, Guangan He, et al.
Cancers|May 1, 2019
Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian CancerJing Guo, Wei-Lei Yang, Daewoo Pak, et al.
Gynecologic Oncology|September 1, 1990
High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancerE J Shpall, D Clarke-Pearson, J T Soper, et al.
Cancer|April 25, 2018
Potentially inappropriate medication use in older patients with breast and colorectal cancerMeghan S Karuturi, Holly M Holmes, Xiudong Lei, et al.
American Journal of Obstetrics and Gynecology|July 1, 1986
The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancerJ M Niloff, R C Knapp, P T Lavin, et al.
Experimental Cell Research|August 1, 1993
Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cellsY J Lidor, F J Xu, O Martínez-Maza, et al.
Pageof 56

Showing results (361-370 of 560) with videos related to

Sort By:
Pageof 56
Biochimica Et Biophysica Acta|June 22, 2001
Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHIR Z Luo, H Peng, F Xu, et al.
Cancer Research|December 1, 1987
Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumorsW P Peters, W D Henner, L B Grochow, et al.
International Journal of Cancer|October 15, 1994
The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxinF J Xu, C M Boyer, D S Bae, et al.
Gynecologic Oncology|May 29, 2007
Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragmentDonna Badgwell, Zhen Lu, Laurence Cole, et al.
Journal of the National Cancer Institute|August 5, 2011
The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cellsXiao-Feng Le, Weiqun Mao, Guangan He, et al.
Cancers|May 1, 2019
Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian CancerJing Guo, Wei-Lei Yang, Daewoo Pak, et al.
Gynecologic Oncology|September 1, 1990
High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancerE J Shpall, D Clarke-Pearson, J T Soper, et al.
Cancer|April 25, 2018
Potentially inappropriate medication use in older patients with breast and colorectal cancerMeghan S Karuturi, Holly M Holmes, Xiudong Lei, et al.
American Journal of Obstetrics and Gynecology|July 1, 1986
The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancerJ M Niloff, R C Knapp, P T Lavin, et al.
Experimental Cell Research|August 1, 1993
Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cellsY J Lidor, F J Xu, O Martínez-Maza, et al.
Pageof 56